Middle East respiratory syndrome coronavirus infection medical therapy: Difference between revisions
Joao Silva (talk | contribs) |
Joao Silva (talk | contribs) |
||
| Line 12: | Line 12: | ||
*'''[[Intravenous immunoglobulin]]''' - | *'''[[Intravenous immunoglobulin]]''' - | ||
*'''[[Interferon]]''' - | *'''[[Interferon]]''' - | ||
*'''[[HIV]] [[Protease | *'''[[HIV]] [[Protease inhibitors]]''' - | ||
*'''[[Ribavirin]]''' - | *'''[[Ribavirin]]''' - | ||
*'''[[Corticosteroids]]''' - | *'''[[Corticosteroids]]''' - | ||
Revision as of 19:16, 17 June 2014
|
Middle East Respiratory Syndrome Coronavirus Infection Microchapters |
|
Differentiating Middle East Respiratory Syndrome Coronavirus Infection from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Middle East respiratory syndrome coronavirus infection medical therapy On the Web |
|
American Roentgen Ray Society Images of Middle East respiratory syndrome coronavirus infection medical therapy |
|
FDA on Middle East respiratory syndrome coronavirus infection medical therapy |
|
CDC on Middle East respiratory syndrome coronavirus infection medical therapy |
|
Middle East respiratory syndrome coronavirus infection medical therapy in the news |
|
Blogs on Middle East respiratory syndrome coronavirus infection medical therapy |
|
Directions to Hospitals Treating Middle East respiratory syndrome coronavirus infection |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: João André Alves Silva, M.D. [2]
Overview
Middle East Respiratory Syndrome (MERS) is a viral respiratory illness. It is caused by an emerging coronavirus, specifically a betacoronavirus called MERS-CoV (Middle East Respiratory Syndrome Coronavirus), first discovered in 2012. Being a relatively novel virus, treatment options are very limited, with no antiviral therapy approved for treating patients yet. Outbreaks of MERS-CoV represent a great challenge since there is very limited time to develop and test new pharmaceutical drugs. Up until now, supportive medical care, along with untested convalescent plasma, have been the only treatment options. However, reuse of drugs for other viruses is presenting as an attractive alternative for MERS-CoV.[1]
Medical Therapy
MERS represents a great challenge in terms of treatment because it is caused by a relatively novel virus, to which there is no specific approved therapy yet. According to the International Severe Acute Respiratory & Emerging Infection Consortium (ISARIC), supportive medical care continues to be the approved treatment for MERS. Recent studies are showing the potential use of other drugs and therapies to treat MERS-CoV, however, lack of evidence makes these new therapies uncertain.[1] ISARIC recommends, additionally to routine investigations, that some approaches are more worth of consideration for experiment. These include:[2]
- Convalescent plasma - this therapy, along with others possessing neutralizing antibodies, has the strongest evidence for intervention. Plasma from patients who recovered from MERS-CoV infection contains neutralizing antibodies, which represents the best therapy to neutralize the extracellular virus.
- Intravenous immunoglobulin -
- Interferon -
- HIV Protease inhibitors -
- Ribavirin -
- Corticosteroids -
- Nitazoxanide -
References
- ↑ 1.0 1.1 Dyall J, Coleman CM, Hart BJ, Venkataraman T, Holbrook MR, Kindrachuk J; et al. (2014). "Repurposing of clinically developed drugs for treatment of Middle East Respiratory Coronavirus Infection". Antimicrob Agents Chemother. doi:10.1128/AAC.03036-14. PMID 24841273.
- ↑ "Treatment of MERS-CoV: Decision Support Tool".